Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2017

Using a multidisciplinary meeting to provide contemporaneous breast cancer data (#145)

June Rose 1 , Amy Hains 1 , Karen Partridge 1
  1. Illawarra Shoalhaven Local Health District, WOLLONGONG, NSW, Australia


To provide feedback to clinicians on breast cancer cases at the beginning of the patients’ journey


Data was collated for patients discussed at fortnightly breast cancer multidisciplinary meetings (MDM) between 01/07/2016 and 30/06/2017. Clinicians’ referral forms, patients’ histopathology results, meeting recommendations, and documentation in the oncology information system (OIS) were used to source data.


278 cases were discussed: 29 patients presented with disease progression or recurrence; 8 had a benign lesion; a diagnosis of an unknown primary was deemed not to be breast cancer; and 240 patients with a newly diagnosed breast cancer were presented. An additional 24 patients were referred to the MDM but not discussed.

Referral forms for newly diagnosed patients indicated: 3 were males; the mean age of all at diagnosis was 62 years (median 63, range 25 to 93 years). Symptomatic / self-detected accounted for 53% (n127) of presentations, with 28% (n68) being diagnosed by Breast Screen.

Histopathology revealed 81.25% (n195) to be ductal carcinomas; with 10% (n24) of all cases being in situ cancers. Three patients had bi-lateral cancers; 22 were triple negative and 27 HER2 positive.  With the exception of one, who declined treatment, all HER2 positive cases had Trastuzumab included in their neo and/or adjuvant chemotherapy protocol. 

Using MDM summaries and OIS records, staging was extrapolated for all newly diagnosed cases; with stage IA (n91) and IIA (n56) accounting for 60% of cases. Wide local excision was the initial surgery for 68.3% (n164); unilateral mastectomy the surgical intervention for 58, bilateral mastectomy for 9; and sentinel lymph node biopsies were performed on 72.5% (n174) of cases.


MDM data is a rich contemporaneous source of data that can be used to identify eligible patients for inclusion in clinical trials, genetic consultation; and evaluation of adherence to MDM recommendations.